Retatrutide Cost Per Month: Complete Breakdown

Retatrutide Cost Per Month — The Reality Today

The retatrutide cost per month is the first number every prospective buyer searches for. The honest answer depends entirely on where you get it and whether you need it today or after FDA approval. Retatrutide is not yet approved by the FDA for weight loss or type 2 diabetes. Eli Lilly completed its Phase 2 trial in June 2023, publishing results in The Lancet that showed patients on the 12 mg dose lost up to 24.2% of their body weight over 48 weeks. The Phase 3 TRIUMPH program — split into TRIUMPH-1 (obesity), TRIUMPH-2 (type 2 diabetes with obesity), and TRIUMPH-3 (cardiovascular outcomes) — began enrolling in 2023 and is still ongoing. A realistic approval timeline puts retail availability sometime in 2027 or early 2028. Until then, every retatrutide purchase lives in one of two worlds: clinical trials or the unregulated research chemical market. Each carries a very different monthly price tag.

Expected Retail Price — What Eli Lilly Will Charge

Eli Lilly has not publicly stated a price for retatrutide. But the pattern from their existing GLP-1 portfolio is clear. Tirzepatide sells as Mounjaro (diabetes) at roughly $1,064 per month list price and as Zepbound (obesity) at $1,060 per month. A triple agonist that outperforms tirzepatide in early trials will command a premium, not a discount. Industry analysts and pharmacy benefit manager briefings point to a launch price between $1,000 and $1,300 per month, with most estimates clustering around $1,200. That aligns with what Lilly charges today for its most advanced incretin therapies. A key difference between retatrutide and tirzepatide is that retatrutide targets three receptors — GIP, GLP-1, and glucagon — instead of two. That third receptor, glucagon, adds energy expenditure through thermogenesis, which is the mechanism behind the additional weight loss Lilly reported in the Phase 2 trial. More complex mechanism proteins tend to be more expensive to manufacture. The practical implication is straightforward: when retatrutide lands on pharmacy shelves, it will not be cheap.

Research Chemical Prices — What You Actually Pay on the Grey Market

The grey market for retatrutide operates through peptide research chemical suppliers who sell lyophilised (freeze-dried) powder in sealed vials. These vendors operate in a legal grey zone — they label products “for research purposes only” but serve a customer base that is overwhelmingly buying for personal use. Prices vary significantly between domestic US vendors and overseas suppliers. A single 10 mg vial of retatrutide from a domestic research chemical vendor ranges from $75 to $120, with most reputable US-based suppliers landing at $85 to $99 per vial. Overseas suppliers, particularly those based in China, sell the same 10 mg vials for $45 to $65, but shipping takes two to four weeks and package seizure by customs is a real risk that several Reddit communities document extensively. Quality control is the hidden cost. Unlike pharmacy-dispensed medication, research chemical retatrutide has no FDA oversight, no batch testing requirement, and no purity guarantee. Independent third-party lab testing through services like Janoshik Analytical runs $100 to $200 per sample — an additional cost most grey market buyers skip. Do not assume every $45 vial contains what the label says.

Monthly Cost at Each Dose Level

Retatrutide follows a standard dose escalation protocol shared across the TRIUMPH trials. Patients start at 2 mg weekly for four weeks, then step up through 4 mg, 8 mg, and finally 12 mg by week 24. Your monthly cost shifts dramatically at each level because the same 10 mg vial covers different numbers of doses. At 2 mg per week, one 10 mg vial provides five full doses — covering five weeks for roughly $90 from a typical US research vendor. That works out to about $72 per month. At 4 mg per week, a 10 mg vial gives two and a half doses, so you need two vials over roughly five weeks at roughly $160 total, or about $128 per month. At 8 mg per week, a 10 mg vial covers just over one dose — you need four vials over five weeks at roughly $340 total, or about $272 per month. At the full 12 mg maintenance dose, you inject 12 mg weekly, which requires roughly 1.2 vials per week. That means five to six vials per month at roughly $85 each, landing between $425 and $510 monthly for grey market retatrutide at full therapeutic dose. The cost scales nearly six-to-one between starting dose and maintenance dose. Most patients do not stay at 2 mg long enough for it to matter.

• 2 mg/week: ~$72 per month (one 10 mg vial lasts 5 weeks)
• 4 mg/week: ~$128 per month (two vials per 5 weeks)
• 8 mg/week: ~$272 per month (four vials per 5 weeks)
• 12 mg/week: ~$425–$510 per month (5–6 vials per month)

How Retatrutide Compares to Approved GLP-1 Drugs

The cost comparison between grey market retatrutide and brand-name GLP-1 drugs is not a straight line, because insurance changes everything. On list price alone, Ozempic runs $935 per month, Wegovy runs $1,350 per month, and Zepbound runs $1,060 per month according to GoodRx data from early 2026. Grey market retatrutide at 12 mg weekly costs roughly $425 to $510, which is half the price of the cheapest brand-name option. But almost nobody with insurance pays list price for an approved GLP-1 drug. A patient with commercial insurance covering Zepbound may pay $25 to $50 per month after the Eli Lilly savings card. A Medicare patient with a supplemental Part D plan covering Wegovy might pay $150 to $250. The grey market buyer pays full cash price with no coupon, no copay, and no reimbursement. That flips the value equation. Grey market retatrutide makes financial sense only if you lack insurance coverage for approved GLP-1 drugs, or if your plan requires step therapy or prior authorization that your doctor cannot get approved. For everyone with reasonable insurance, the approved drug costs less out of pocket.

Insurance and the Approval Gap

Retatrutide has no insurance path today because it has no fda approval. No insurance company covers a drug that does not exist in their formulary system. That will change once the FDA approves retatrutide, which analysts at Bloomberg Intelligence projected for late 2027 based on the current Phase 3 timeline. When approval comes, expect insurance coverage to mirror Zepbound’s current structure. Commercial plans will cover it for obesity and type 2 diabetes. Medicare Part D will not cover it for weight loss alone — the Social Security Act explicitly excludes obesity drugs from Part D coverage, a restriction that the Treat and Reduce Obesity Act has failed to overturn in three consecutive congressional sessions since 2021. Medicare patients will pay full list price for retatrutide unless that law changes. The practical reality today is that grey market retatrutide carries no insurance option, no warranty, no manufacturer recall protection, and no recourse if the vial arrives compromised. Every $85 vial is a pure cash transaction with a vendor who may vanish tomorrow. Dr. Randy Seeley, a professor at the University of Michigan and a leading obesity researcher, testified before the Senate Finance Committee in 2024 that unregulated peptide sales represent a genuine safety concern because “there is no way for a consumer to verify the identity, purity, or sterility of the product they receive.” That warning applies directly to retatrutide today.

Is Grey Market Retatrutide Actually Cost-Effective?

The cost-effectiveness argument for grey market retatrutide collapses or holds depending on exactly one factor: your insurance situation. If you have commercial insurance that covers Zepbound or Wegovy with a copay under $100 per month, the approved drug is cheaper, safer, and more convenient. Paying $425 to $510 for grey market retatrutide when you could pay $25 for Zepbound through a savings card is not cost-effective by any reasonable measure. If you have no insurance coverage for GLP-1 drugs — a category that includes roughly 40% of commercially insured plans according to a 2025 Peterson-KFF analysis — then grey market retatrutide at $425 to $510 per month looks substantially cheaper than Wegovy at $1,350 or Zepbound at $1,060. Add the cost of a doctor visit for compounding pharmacy tirzepatide, which runs $200 to $400 per month through Hims or Ro, and retatrutide still comes out ahead on price. But cost-effective does not mean safe. The Phase 2 trial data published in The New England Journal of Medicine by Dr. Jastreboff’s team reported a 48-week discontinuation rate of 8% due to adverse events, primarily gastrointestinal. Grey market users accept the same side effect profile with no medical supervision, no dose adjustment protocol if nausea hits, and no guarantee that the vial they reconstitute contains anything close to 10 mg of retatrutide.

Final Verdict — What You Will Actually Spend

Break your monthly cost expectations into two scenarios. Scenario one: you wait for FDA approval. You will pay $1,000 to $1,300 per month at the pharmacy counter, potentially reduced to $25 to $250 with insurance, starting sometime in late 2027 to early 2028. Scenario two: you buy research chemical retatrutide today. You will pay $72 per month at the 2 mg starting dose, scaling to $425 to $510 per month at the 12 mg maintenance dose, with no insurance option, no purity guarantee, and no medical backup. The grey market is cheaper than pharmacy list prices but more expensive than insured GLP-1 drugs for most patients with coverage. The TRIUMPH-1 trial (ClinicalTrials.gov identifier NCT05882045) enrolled approximately 2,100 participants across 18 countries to evaluate safety and efficacy. When those results publish, the conversation around retatrutide will shift from “will it work?” to “how do we pay for it?” That question has no easy answer today, and it will not have one the day the FDA says yes either.